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In the present study, we investigated the association between the 4-repeat allele at the dopamine receptor D4 (DRD4) gene and the
response to treatment with methylphenidate (MPH) in Korean children with attention deficit hyperactivity disorder (ADHD). The study
subjects were 83 children with ADHD (8.4071.73 years) who were recruited from two child psychiatric clinics in South Korea. All of the
drug-naive ADHD children were treated with MPH for about 8 weeks. An improvement of more than 50% in the ADHD Rating Scale-IV
(ARS) scores after 8 weeks of treatment compared with the baseline ARS scores before the treatment was considered as a ‘good
response’, whereas an improvement of less than (or equal to?) 50% was considered as a ‘poor response’. After the genotyping for DRD4
was performed, we investigated the association between the genotype at DRD4 and the response to MPH treatment. We performed a
comparison of the response to MPH treatment between the two largest groups, viz. the subjects with and without the 4/4 genotype at
DRD4. According to the ARS scores of the subjects as assessed by their parents and by their teachers, we found that while 71.1 and
80.0% (32/45 and 24/30), respectively, of those with a good response to MPH treatment showed the 4/4 genotype at DRD4, only 31.6
and 37.7% (12/38 and 20/53), respectively, of those with a poor response to MPH treatment showed the 4/4 genotype at DRD4
(Pearson w2-values¼ 12.926 and 13.737, respectively, both df¼ 1, and both po0.01). Our findings support the existence of an
association between the 4-repeat allele at DRD4 and good response to MPH in Korean ADHD children.
Neuropsychopharmacology (2007) 32, 1377–1383. doi:10.1038/sj.npp.1301244; published online 1 November 2006
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INTRODUCTION
Attention deficit hyperactivity disorder (ADHD), which is
characterized by inattention, hyperactivity, and impulsive
behavior, is a condition which has various etiologies
(Barkley, 1990). ADHD is frequent in school age children,
4–10% of whom are afflicted with this disorder, and causes
long-term academic, social, emotional, and psychological
problems (Hong and Oh, 1980; Szatmari et al, 1989; Cho
and Shin, 1991). ADHD continues into adulthood in some
cases and is a risk factor for antisocial behavior and drug
abuse in ADHD children after they grow up (Mannuzza
et al, 1993; Weiss and Hechtman, 1993). Many familial and
genetic studies showed that the hereditary factor is
important in the mechanism of ADHD development
(Waldman et al, 1998; Faraone and Doyle, 2000).
Many candidate genes have been mentioned in relation to
ADHD in several genetic studies. Methylphenidate (MPH),
which is known to be effective for improving ADHD
symptoms, operates through the mechanism of inhibiting
the dopamine transporter (DAT) and is known to be
effective for the attention deficient problems and impulsive
behaviors of ADHD (Spencer et al, 1996). The results
obtained from these studies suggest that the DAT gene
(DAT1) is a potential risk factor for ADHD.
Separately, the dopamine receptor D4 (DRD4) gene has
also been regarded as a leading candidate gene for ADHD. A
study conducted in 1996 with 39 ADHD affected children
and 39 normal children first reported the association
between ADHD and DRD4 after finding the 7-repeat allele
of the DRD4 exon III 48 bp variable number of tandem
repeats (VNTR) polymorphism (in the ADHD children?
LaHoste et al, 1996). This finding was subsequently
supported by other studies. Two studies proved that there
was a greater transmission of the 7-repeat allele in ADHD
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children after analyzing a population of 52 nuclear families
with the haplotype relative risk (HRR) method (Terwilliger
and Ott, 1992; Swanson et al, 1998). Many studies have been
conducted in an attempt to define the association of the
DRD4 gene with ADHD (Castellanos et al, 1998; Rowe et al,
1998; Smalley et al, 1998; Faraone et al, 1999; Sunohara et al,
2000).
One of these studies asserted that there was no significant
correlation between ADHD and the DRD4 polymorphism
after comparing the frequency of the 7-repeat allele of DRD4
in children with acute ADHD and normal children. In a
recent study using the transmission disequilibrium test
(TDT), the frequency of transmission of the 7-repeat allele
of DRD4 was found to be increased in families in which the
children were afflicted with ADHD (Sunohara et al, 2000).
Researchers have continued to attempt to prove the
preferential transmission pattern of the 7-repeat allele of
DRD4 exon III in relation to ADHD by using refined
analysis techniques and different ethnic groups (Hawi et al,
2000; Sunohara et al, 2000).
At the same time, many studies have investigated the
possible association between polymorphisms in genes
involved in ADHD and the response to the medication
treatment of ADHD. It is known that MPH, which improves
ADHD symptoms by blocking DAT, is effective in 70% of
ADHD children. However, research on the factors that could
predict the degree of response to drug treatment is still in its
infancy. Winsberg and Comings (1999) reported that the
homozygosity of the 10-repeat allele at DAT1 was related to
a poor response to MPH treatment in 30 African-American
ADHD children. A double-blind study in 50 Brazilian
ADHD boys also showed that the 10/10 genotype at DAT1
was significantly associated with the response to MPH
treatment (Roman et al, 2002). Rohde et al (2003) recently
reported that there was a difference in the regional cerebral
blood flow (rCBF) measured with SPECT between the two
groups, with and without homozygosity for the 10-repeat
allele at DAT1, in eight ADHD boys who responded to MPH.
In our previous study, we found a significant association
between the homozygosity for the 10-repeat allele at DAT1
and the response to MPH treatment in Korean children with
ADHD (Cheon et al, 2005).
The 7-repeat allele of a 48 bp VNTR) in the exon-III of
DRD4 was identified as a risk allele and has been
investigated in various association studies, with both
positive and negative results. In addition, the presence of
the 7-repeat allele of the DRD4 gene seems to be associated
with a poor response to MPH treatment in ADHD (Seeger
et al, 2001). Hamarman et al (2004) reported that ADHD
children possessing the DRD4 7-repeat allele require higher
doses of MPH for symptom improvement and symptom
normalization, and suggested the possibility that the 7-
repeat allele of the DRD4 gene VNTR polymorphism
correlates with treatment outcome. This 7-repeat allele,
however, is rarely present in Asian populations, such as
Chinese, Japanese, and Korean children (Lichter et al, 1993).
Many previous studies have reported that the most frequent
allele and genotype of DRD4 in the Korean population were
the 4-repeat allele and 4/4, respectively (Lee et al, 2003a, b).
In addition, the common 4-repeat allele has been identified
as the conserved ancestral allele (Ding et al, 2002; Wang
et al, 2004). Furthermore, the available biochemical data
indicate that the 4-repeat protein has a significantly less
blunted response to dopamine than the 2-repeat and 7-
repeat proteins (Asghari et al, 1995). One preliminary
report suggested that ADHD children having the 7-repeat
allele but not having a 4-repeat allele of the DRD4 exon-III
VNTR polymorphism showed a worse response to treat-
ment with MPH than ADHD children having the 4-repeat
allele, owing to the decreased function of the D4 receptor
(Sallee, 2004). It was particularly suggested that the 4-repeat
allele at DRD4 could be a predictor of the response to
treatment with both MPH and atomoxetine.
We hypothesized that the 4-repeat allele at the DRD4 gene
might be associated with a better response of ADHD
children to treatment with MPH. Thus, in the present study,
we investigated the association between the genotype at the
DRD4 gene and the response to MPH treatment in Korean
children with ADHD.
MATERIALS AND METHODS
Subjects
The present study comprised 83 ADHD children (8.2371.78
years) who were recruited from two child psychiatric clinics
in South Korea. The children selected for the ADHD group
were those children (1) who were diagnosed as having
ADHD combined type according to the DSM-IV Diagnostic
Criteria of Mental Disorders, (2) who were aged 7–12 years,
(3) who and whose parents/guardians agreed to participate
in the study, with provision of informed consent before
inclusion, (4) who were never exposed to psychostimulants
such as MPH. We excluded those children (1) with tic
symptoms, obsessive compulsive symptoms or any other
mental disorders, (2) who had a past history or were
currently suffering from brain damage or convulsive
disorder, (3) who were mentally handicapped or had
autism, language difficulties, or developmental problems
including learning disability, (4) who or whose parents/
guardians did not agree to the study.
This study was approved by the institutional review
boards for human subjects at the University of Yonsei,
Yongdong Severance Hospital, and Seoul National Uni-
versity hospital in Seoul, Korea.
Diagnostic and Evaluation Tools of Clinical Symptoms
(1) Kiddie-Schedule for Affective Disorders and Schizo-
phrenia-Present and Lifetime Version (K-SADS-PL)
(Kaufman et al, 1997): the Korean version of K-SADS-
PL was translated by Kim et al (2004) and its validity
and reliability for the evaluation of ADHD, tic disorder,
and oppositional defiant disorder were previously
validated.
(2) ADHD Rating Scale-IV (ARS): composed of a total of
18 items, ARS is the ADHD symptom severity scale
designed by DuPaul et al (1998) according to the
DSM-IV Diagnostic Criteria of Mental Disorders. Each
item has a 4-point scale ranging from 0 to 3. The 18
items are composed of nine items reflecting the
symptoms related to inattention and nine items
reflecting the symptoms related to hyperactivity and
DRD4-4R and treatment response in ADHD
K-A Cheon et al
1378
Neuropsychopharmacology
impulsivity. Either the parents or teacher can complete
the scale for the ADHD child and both scales have the
same items. The Korean version of ARS was standar-
dized by So et al (2002).
MPH Administration and Treatment Response
All of the ADHD subjects were administered MPH for 8
weeks. The dosages were increased up to a sufficient dose to
achieve the therapeutic effect, based on the parents’ reports
of symptom improvement and side effects. Then, these
dosage levels were maintained for 8 weeks. The ARS scores
were assessed by the parents and teachers before and after
the 8-week course of MPH treatment, in order to assess the
improvement of the ADHD symptoms.
An improvement in the ARS score after 8 weeks of
treatment of more than 50% compared with the baseline
ARS score before the treatment was considered a ‘good
response’, whereas an improvement of less than 50% was
considered a ‘poor response’. All of the procedures were
performed by medical staff who were blinded to the results
of the DRD4 genotyping.
Preparation of Genomic DNA
Genomic DNA was extracted from blood lymphocytes using
a Genomic DNA Extraction kit (Bioneer, Korea).
DRD4-Exon3 Genotype Determination
The DRD4-exon III repeat region was genotyped by a PCR-
based length polymorphism (test/method?).
The oligonucleotide primers (50-ACCACCACCGGCAG
GACCCTCATGGCCTTGCGCTC-30 and 50-CTTCCTACCCT
GCCCGCTCATGCTGCTGCTCTACTGG-30) were used to
generate the DRD4-exon III polymorphic region (2–10
variable repeat units, 1 unit¼ 48 bp). PCR amplification was
performed with a volume of 20 ml containing 100 ng of
genomic DNA, 10 pmol of each primer, 1 PFU PCR buffer
(Solgent, Korea), 400 mM dATP, dTTP and dCTP, 200 mM
dGTP (Solgent, Korea), 200 mM 7-Deaza-dGTP (Boehringer
Mannheim), 5% DMSO, and 2 U Solgent PFU Taq. The
reaction consisted of a denaturation step at 981C for 5 min,
followed by 35 cycles consisting of 981C for 45 s, 551C for
45 s, and 721C for 1 min 30 s, with a final extension step at
721C for 5 min. Thermal cycling was performed on an MJ
research PTC-100 thermal cycler. The amplification pro-
ducts were electrophoresed on a 2% agarose gel and
visualized by EtBR staining (Kotler et al, 2000) (Figure 1).
Statistical Analysis
The correlation between the genotype at DRD4 and the
response to MPH treatment was evaluated using the w2 (Chi-
square) test. The level of significance was 5% (two-tailed).
RESULTS
Demographic and Clinical Characteristics
The 83 ADHD children (mean age¼ 8.4071.73 years)
comprised 72 boys (mean age¼ 8.3571.77 years) and 11
girls (mean age¼ 8.7371.49 years). The average IQ of the
ADHD subjects was 111.87717.46. The average scores of the
overall symptoms of ADHD according to the ARS, as
measured by the parents and teachers of the ADHD children,
decreased from 34.4178.16 to 30.3378.19, respectively, at
baseline between 17.9575.20 and 17.9874.43, respectively,
after 8 weeks of MPH treatment (Table 1).
Genetic Polymorphisms of DRD4
Among the 83 ADHD children, the 4-repeat allele of the 48-
bp VNTR polymorphism at DRD4 was identified in 123 of
the 166 chromosomes (74.1%) and the 2-repeat allele was
identified in 30 of the 166 chromosomes (18.1%). The 5-
repeat, 6-repeat, and 7-repeat alleles were identified in 5, 3,
and 1 of the 166 chromosomes, respectively (3.0, 1.8, and
0.0%). The distribution of the genotypes for the DRD4
exon-III VNTR was in agreement with the expected values
of the Hardy–Weinberg equilibrium (goodness of fit w2-
value¼ 1.13, df¼ 5, p¼ 0.89). To perform the quality
control of the genotyping method used in this study, we
selected 10 samples randomly and reanalyzed them in a
blind manner. No discrepancies were found. The 4/4
500bp
M : 100 bp size Marker
1: 2/2 repeat type
2: 2/4 repeat type
3: 4/4 repeat type
4: 4/5 repeat type
5: 4/6 repeat type
6: 4/7 repeat typeM 1 2 3 4 5 6
Figure 1 PCR analysis of exon III 48 bp VNTR of the dopamine receptor
4 gene (DRD4).
Table 1 Clinical Characteristics of the ADHD Subjects (N¼ 83)
Characteristics Number (%)
Sex
Male 72 (86.8)
Female 11 (15.5)
Mean7SD
Age (years) 8.4071.77
IQ
Total IQ 111.87717.46
Verbal IQ 112.13718.18
Performance IQ 108.61716.10
CDI 20.8676.89
SD: standard deviation; CDI: childhood depression inventory.
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genotype was observed in 44 ADHD children (53.0%), the
4/2 genotype in 30 (36.1%), the 4/5 genotype in five (6.0%),
the 4/6 genotype in three (3.6%), and the 4/7 genotype in
only one (1.2%).
Correlation between the Genotype at DRD4 and the
Response to MPH Treatment
According to the ARS scores of the children as assessed by
their parents and by their teachers, we found that 71.7 and
80.0% (32/44 and 24/30), respectively, of the subjects with
the 4/4 genotype at DRD4 showed a good response (450%
improvement) to MPH treatment. However, only 22.2 and
16.7% (10/45 and 5/30), respectively, of the subjects with the
4/2 genotype at DRD4 showed a good response to MPH
treatment, and only 4.4 and 3.3% (2/45 and 1/30) of the
subjects with the 4/5 genotype showed a good response to
MPH treatment. None of the subjects with the 4/6 or 4/7
genotype showed a good response to MPH treatment
(Pearson w2-value¼ 13.463 and 14.215, respectively, both
df¼ 4, and both po0.01) (Table 2).
Comparison of the Response to MPH Treatment
between the Subjects with and without the
4/4 Genotype at DRD4
We performed a comparison of the response to MPH
treatment between the two largest groups, viz. the subjects
with and without the 4/4 genotype at DRD4. We found that
the response to MPH treatment, as assessed by the parents
and teachers, was significantly associated with the presence
of the 4/4 genotype at DRD4 (Pearson w2-value¼ 12.926 and
13.737, both df¼ 1, and both po0.01) (Table 3).
No significant differences in the mean age or baseline ARS
scores of the ADHD children, as assessed by their parents, were
found between those with and without the 4/4 genotype of
DRD4. Those ADHD children with the 4/4 genotype of DRD4
had a significantly higher score in the total scales of ARS, as
assessed by their teachers, than those children without the 4/4
genotype of DRD4 (Table 3). We found no significant
differences in the average daily dose of MPH between the
ADHD children with and without the 4/4 genotype, or between
the two largest genotype groups (the subjects with the 4/4
genotype and the 4/2 genotype) (Table 4).
Table 2 Correlation between the Genotype at DRD4 and the
Response of the ADHD Children to the Treatment with
Methylphenidate According to the ARS, as Assessed by their
Parents and Teachersa
Response to MPH
treatment N (% within
response)
Genotype
Poor
(o50%)
Good
(X50%) Total
ADHD
children
4/4 Parenta 12 (31.6%) 32 (71.1%) 44
Teacherb 20 (37.7%) 24 (80.0%)
4/2 Parenta 20 (52.6%) 10 (22.2%) 30
Teacherb 25 (47.2%) 5 (54.5%)
4/5 Parenta 3 (7.9%) 2 (4.4%) 5
Teacherb 4 (7.5%) 1 (3.3%)
4/6 Parenta 2 (5.3%) 1 (2.2%) 3
Teacherb 3 (5.7%) 0 (0%)
4/7 Parenta 1 (2.6%) 0 (0%) 1
Teacherb 1 (1.9%) 0 (0%)
Total Parenta 38 45 83
Teacherb 53 30
The w2-test (by Fisher’s Exact test) was used for correlation.
aPearson w2-value¼ 13.463, df¼ 4, po0.01.
bPearson w2-value¼ 14.215, df¼ 4, po0.01 (by Fisher’s Exact test).
Parent: according to ARS assessed by parent; teacher: according to ARS
assessed by teacher; MPH: methylphenidate.
Table 3 Correlation between the 4/4 Genotype at DRD4 and the Response of the ADHD Children to the Treatment with
Methylphenidate According to the ARS, as Assessed by Their Parents and Teachersa
Mean total ARS score
(mean7SD)
Response to MPH treatment N
(% within response)
Baseline Post-MPH Poor Good Total
ADHD children With 4/4 genotype Parenta 35.7077.97 16.9174.23 12 (31.6%) 32 (71.1%) 44
Teacherb 32.0278.37 17.5274.04 20 (37.7%) 24 (80.0%)
Without 4/4 genotype Parenta 32.9578.23* 19.1375.94 26 (68.4%) 13 (28.9%) 39
Teacherb 28.4177.63* 18.4974.84 33 (62.3%) 6 (20.0%)
Total Parenta 34.4178.16 17.9575.20 38 45 83
Teacherb 30.3378.19 17.9874.43 53 30
The w2-test (by Fisher’s Exact test) was used for correlation, Parent: according to ARS assessed by parent; teacher: according to ARS assessed by teacher.
aPearson w2-value¼ 12.926, df¼ 1, po0.01.
bPearson w2-value¼ 13.737, df¼ 1, po0.01 (by Fisher’s Exact test).
*po0.05 (by Student t-test); MPH: methylphenidate.
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We found a proportionate distribution of males and
females in the two genotype or treatment response groups.
The numbers of males and females with the 4/4 genotype at
DRD4 were 38 (52.8%) out of 72 and five (54.5%) out of 11,
respectively. No significant difference in the gender
distribution was found between the two genotype groups
(Pearson w2-value¼ 0.012, df¼ 1, and p¼ 0.913). We found
that the numbers of ADHD children who were considered
by their parents to exhibit a good response to treatment
were 39 (54.2%) out of 72 males and six (54.5%) out of 11
females (Pearson w2-value¼ 0.001, df¼ 1, and p¼ 0.981),
and the numbers of ADHD children who were considered
by their teachers to exhibit a good response to treatment
were 24 (33.3%) out of 72 males and 6 (54.5%) out of 11
females (Pearson w2-value¼ 1.860, df¼ 1, and p¼ 1.173).
No significant difference in the gender distribution was
found between the good and poor treatment response
groups.
DISCUSSION
This study identified a significant association between the
DRD4 exon III 48-bp VNTR polymorphism and the
response to MPH treatment in ADHD children. Those
subjects homozygous for the 4-repeat allele at DRD4
showed a better response to MPH treatment than those
who were not homozygous for this allele. These findings are
relatively consistent with the preliminary results of the 2004
Sallee study. In addition, the findings of the present study
are important, because it was conducted with only Korean
ADHD children.
There have been few studies that defined the association
of ADHD and the 4-repeat allele of DRD4. Barr et al (2000)
conducted a TDT analysis to determine the association
between ADHD and DRD4 and found significant evidence
for the biased transmission of the 7-repeat allele and
nontransmission of the 4-repeat allele. They interpreted this
interesting finding of the nontransmission of the 4-repeat
allele as compensation for the excess transmission of the
7-repeat allele, thereby signaling the possibility that the
4-repeat allele might be a protective factor in reducing the
risk of developing ADHD. These findings are in agreement
with those of other recent studies (Ding et al, 2002; Wang
et al, 2004; Asghari et al, 1995) and are supported by the
findings of the present study.
Recently, researchers have stepped up their efforts to
estimate the treatment outcomes for mental illness by
investigating the effects of pharmacogenetics. Roses (2001)
predicted the completion of SNP profiles in patients who
showed a clinically positive response to medication treat-
ment for psychiatric disorders. However, little pharmaco-
genetic research has been conducted into the treatment of
children with psychiatric disorders such as ADHD. Even
though there have been a few pharmacogenetic studies
dealing with children, their sample sizes tended to be too
small (Anderson and Cook, 2000). The present study
marked an important milestone in genetic approaches to
increasing the understanding of the mechanism behind
ADHD symptoms in children, since it used a larger sample
size than previous studies investigating the association of
DRD4 with ADHD. The existing studies, which were mainly
conducted with Europeans or Caucasians, reported poor
treatment outcomes in the presence of the 7-repeat allele
of the DRD4 VNTR polymorphism (Seeger et al, 2001;
Hamarman et al, 2004; Sallee, 2004). However, the 7-repeat
allele of the DRD4 exon III VNTR polymorphism has not
been found in studies conducted with Asian people,
including the present study and, consequently, it is difficult
to verify the research findings obtained from white ADHD
children in Asian ADHD children. Whereas there was a
preliminary study suggesting the possible involvement of
the 4-repeat allele in ADHD treatment (Sallee, 2004), the
present study provided evidence that the same allele had
beneficial effects in the treatment of Korean ADHD
children, and has therefore significantly advanced the state
of research in this promising treatment field.
Recently, Leung et al (2005) reported a significantly
increased prevalence of the 2-repeat allele at DRD4 in Han
Chinese ADHD children, whereas none of them had the
DRD4 7-repeat allele. In this context, it should be noted that
a biochemical analysis conducted in a previous study
demonstrated that the 7-repeat protein has a threefold
reduced ability to reduce cAMP levels, as compared to the
4-repeat protein. In this same study, the 2-repeat protein
also exhibited an inhibited cAMP response, which was
midway between those of the 4-repeat and 7-repeat variants
(Asghari et al, 1995). The resequencing analysis conducted
by Wang et al (2004) showed unequivocally that the 2-
repeat allele in Asians is a recombination product of the
7-repeat allele. The present study also identified the
presence of the 2-repeat allele in 78.1% of the subjects
not homozygous for the 4-repeat allele at DRD4, which
was statistically significant (po0.01). It is likely that the
2-repeat allele at DRD4 was related to the poor outcome of
MPH treatment. Further studies with larger sample sizes are
therefore needed to confirm the association of the 2-repeat
allele with ADHD or poor treatment outcomes in ADHD
children.
This study had some limitations. First, other socio-
psychological factors that might have influenced the
outcome of the MPH treatment in the ADHD subjects were
not excluded. In the selection of the subjects, the authors
Table 4 Comparison of the Dosage of MPH Per Day between
the ADHD Children with and without the 4/4 Genotype and
between Those with the 4/4 and 4/2 Genotypes at DRD4
MPH dose (mg/day) mean7SD
Final dose Average dose p-value
With 4/4 (N¼ 44) 24.9177.12 21.0875.67 0.669
W/O 4/4 (N¼ 39) 24.2177.81 20.2174.76 0.452
With 4/4 (N¼ 44) 24.9177.12 21.0875.67 0.619
With 4/2 (N¼ 31) 24.0677.36 19.9274.25 0.338
Total subjects (N¼ 83) 24.5877.41 20.6777.25
SD: standard deviation, with 4/4: ADHD children with homozygosity for the
4-repeat allele at DRD4, W/O 4/4: ADHD children without homozygosity for
the 4-repeat allele at DRD4, with 4/2: ADHD children with the 4/2 genotype
at DRD4.
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tried to minimize the variables affecting the treatment
outcome by excluding children with mental disorders
concomitant to ADHD. More studies need to be conducted
with more precise control of the variables that may affect
the treatment outcome in ADHD children. Secondly, those
subjects homozygous for the 4-repeat allele at DRD4
showed a higher ARS score at baseline, as measured by
the teachers, than those subjects who were not homozygous
for this allele. This means that a big change in the ARS score
between baseline and after treatment might have been
interpreted as a good outcome in those subjects homo-
zygous for the 4-repeat allele, as demonstrated in the
teachers’ assessment. Despite the possibility that those
subjects homozygous for the 4-repeat allele might have
shown a poor response to MPH treatment due to their more
severe symptoms, the ARS score in this group significantly
improved, thus supporting the finding of a good outcome in
the group homozygous to the 4-repeat allele. Thirdly, in this
study, the subjects were divided into two groups according
to the presence or absence of the 4-repeat allele of the DRD4
exon III VNTR polymorphism, without considering the
number of 4-repeat alleles. The analysis of the treatment
outcomes corresponding to the absence of or presence of
one or two 4-repeat alleles would provide more specific
evidence for the relationship between the 4-repeat allele at
DRD4 and ADHD. As only three of the 39 subjects (7.7%)
with the heterozygous genotype of DRD4 did not have any
4-repeat alleles, however, it was not statistically meaningful
to form a separate group. The association between the
change in the treatment outcome and the number of 4-
repeat alleles needs to be further investigated with a larger
sample size.
Despite these limitations, this study is the first of its kind
in the area of pharmacogenetics to design a treatment plan
for the management of ADHD in an Asian population. To
use the functions of the DRD4 gene as a predictor for
treatment outcome in patients with ADHD, further studies
with larger sample sizes need to be conducted in various
Asian ethnic groups.
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